Form 4: Guardant Health Exec Reports Stock Transactions

Guardant Health's Chief Commercial Officer, Chris Freeman, reported transactions involving the acquisition of common stock and restricted stock units.

Summary

• Chris Freeman, Chief Commercial Officer at Guardant Health, Inc., reported several transactions on July 1, 2026.
• These transactions include the acquisition of common stock through the vesting of restricted stock units (RSUs).
• Specifically, 1,928 shares were acquired under an RSU award granted on November 7, 2022, with a vesting schedule over four years.
• An additional 1,667 shares were acquired from an RSU award granted on December 13, 2023, vesting over three years.
• Furthermore, 2,526 shares were acquired from an RSU award granted on November 8, 2024, vesting over three years.
• Lastly, 1,293 shares were acquired from an RSU award granted on March 12, 2025, vesting over three years.
• A total of 3,141 shares were disposed of at a price of $170.77 per share, with the company retaining some shares for tax withholding obligations.
• Following these transactions, Freeman beneficially owns 65,374 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details routine equity compensation transactions and a disposition for tax withholding, rather than significant strategic or financial performance indicators.

Positives

• Acquisition of common stock through RSU vesting indicates continued equity participation by a key executive.
• The executive's continued ownership of a significant number of shares (65,374) suggests alignment with shareholder interests.

Negatives

• A disposition of 3,141 shares occurred, which could be interpreted as a reduction in direct holdings, though it was for tax withholding.

Future Outlook

The filing details the vesting schedules of various restricted stock unit awards granted to Chris Freeman, indicating future potential acquisitions of common stock as these awards vest over the coming years.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for tracking insider transactions at publicly traded companies like Guardant Health, a leader in the precision oncology diagnostics space. These transactions provide insight into executive compensation and potential insider sentiment.

Stakeholder Impact

• Shareholders: The transactions reflect executive compensation practices and insider ownership levels, which can influence investor perception.
• Employees: The vesting of RSUs for a key executive highlights the company's equity-based compensation strategy.

Next Steps

• Continued vesting of restricted stock units over the next several years as per the outlined schedules.
• Potential future transactions by Chris Freeman as RSU awards vest or based on personal financial planning.

Key Dates

Keywords

Guardant Health, GH, Form 4, SEC Filing, Stock Transaction, Restricted Stock Units, RSU Vesting, Chris Freeman, Chief Commercial Officer, Beneficial Ownership